Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000046742
JPRN-UMIN000046742
Not yet recruiting
未知

Intervention study - Intervention study

Showa University0 sites20 target enrollmentFebruary 1, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsJaw deformity

Overview

Phase
未知
Intervention
Not specified
Conditions
Jaw deformity
Sponsor
Showa University
Enrollment
20
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 1, 2022
End Date
March 30, 2023
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •When communication is not possible

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
PACT: Prevention of Atopy among Children in TrondheimAtopic and allergic diseases in early childhoodatopic eczemaallergic rhinoconjunctivitisasthmaSigns and Symptoms
ISRCTN28090297orwegian University of Science and Technology (Norway)14,000
Completed
Not Applicable
Arteriovenous fistula cannulation in haemodialysis patients
ISRCTN27841616Royal Berkshire and Battle Hospitals NHS Trust (UK)140
Recruiting
Phase 1
An Interventional and Translational Study investigating Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C (CODEBREAK)locally-advanced and unresectable or metastatic NSCLC with KRAS G12CMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 25.1Level: LLTClassification code: 10069759Term: KRAS mutation Class: 10018065Therapeutic area: Diseases [C] - Neoplasms [C04]Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
CTIS2024-510837-16-00Institut Gustave Roussy40
Active, not recruiting
Phase 1
An Interventional and Translational Study investigating Sotorasib in Previously Treated Locally Advanced or Metastatic non-small-cell lung cancerocally-advanced and unresectable or metastatic non-small-cell lung cancer with KRAS G12C mutationTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2021-006958-31-FRGustave Roussy40
Completed
Not Applicable
Does the B-vitamin riboflavin lower blood pressure in individuals with high blood pressure who have a specific genetic make up?HypertensionCirculatory SystemEssential (primary) hypertension
ISRCTN23620802niversity of Ulster (UK)80